Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease (REMODEL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04974099|
Recruitment Status : Recruiting
First Posted : July 23, 2021
Last Update Posted : January 26, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease, with many of those being young children and adolescents. Physicians need better ways to inform decisions on treatment.
The main reason for this research study is to determine if a computer program that formulates a dose based on a patient's blood testing results can better achieve the optimal drug level as compared to standard dosing.
|Condition or disease||Intervention/treatment||Phase|
|Crohn Disease||Device: RoadMAB Drug: Precision dosing with a dashboard||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||The intervention cohort includes patients, age 6-22 years old who have been diagnosed with CD, are naïve to anti-TNF medications and are scheduled to start infliximab (or infliximab biosimilar).|
|Masking:||None (Open Label)|
|Official Title:||Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease|
|Actual Study Start Date :||October 1, 2021|
|Estimated Primary Completion Date :||August 1, 2023|
|Estimated Study Completion Date :||August 1, 2023|
Experimental: RoadMAB dashboard system
The intervention includes utilizing Clinical and Patient Decision Support Software (RoadMABTM) that will guide the selection of the first infliximab dose followed by subsequent infliximab dose and dosing interval during the maintenance phase. During induction, three infusions will occur at 0, 2 and 6 weeks, respectively. The RoadMABTM dashboard will utilize PK modeling software to provide an infliximab starting dose recommendation (range of 5-12 mg/kg) based on the patients biochemical profile. As noted, dosing frequency (weeks) during induction will not be altered during this study. Following the first three doses, the clinician will be informed of their patients PK profile within the RoadMABTM program and with a shared document (paper). RoadMABTM will provide additional dosing recommendations after each infusion (based on the latest drug concentration measures and blood biomarkers) with the final dose and interval selected by the treating physician.
The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
Other Name: Precision dosing with a dashboard
Drug: Precision dosing with a dashboard
The trial is testing whether precision dosing can more reliably achieve the targeted trough concentrations compared to standard dosing
- Obtain safety data for optimal dosing strategy and sample size estimation [ Time Frame: 2 years ]Number of adverse and/or serious adverse events
- Enrollment feasibility [ Time Frame: 2 years ]Evaluate the rate of recruitment
- Completion feasibility [ Time Frame: 2 years ]Number of patients that complete the study
- Rate of patient adherence to stool and blood sample collections [ Time Frame: 2 years ]patient adherence to stool and blood sample collections
- RoadMAB Usability [ Time Frame: 2 years ]Evaluate rate of physician adherence to RoadMAB dosing recommendation
- RoadMAB Efficacy [ Time Frame: 2 years ]Rate of achieving infus3 (Visit 4) infliximab concentration between 16-24 μg/ml as a dichotomous outcome
- Evaluate accuracy of infliximab concentration targets - Median difference infus3 [ Time Frame: 2 years ]Median difference of infus3 (Visit 4) levels between cases and controls
- Evaluate accuracy of infliximab concentration targets - Incidence [ Time Frame: 2 years ]Incidence of achieving infus2 (Visit 3) level between target range of 26-34 μg/ml as a dichotomous outcome
- Evaluate accuracy of infliximab concentration targets - Median difference infus2 [ Time Frame: 2 years ]Median difference of infus2 (Visit 3) levels between cases and controls
- Evaluate accuracy of infliximab concentration targets - Maintenance [ Time Frame: 2 years ]Rates of achieving maintenance targets infus4-6 (Visits 5-7) between 5-10 μg/ml
- Evaluate accuracy of infliximab concentration targets [ Time Frame: 2 years ]Rate of development of antiinfliximab antibodies at any infusion between cases and controls
- Infus4 (Visit 5) and infus6 (Visit 7): Clinical Response [ Time Frame: 2 years ]Improvement in baseline wPCDAI by >17.5 or a wPCDAI<12.5
- Infus4 (Visit 5) and infus6 (Visit 7): Clinical Remission [ Time Frame: 2 years ]wPCDAI <12.5 and off corticosteroids
- Sustained Remission [ Time Frame: 2 years ]wPCDAI <12.5 and off prednisone for all visits from infus4 (Visit 5) to infus6 (Visit 7)
- Infus4 (Visit 5) and Infus6 (Visit 7): Fecal Biochemical Response [ Time Frame: 2 years ]≥50% improvement in fecal calprotectin
- Infus4 (Visit 5) and Infus6 (Visit 7): Fecal Biochemical Remission [ Time Frame: 2 years ]fecal calprotectin <250 μg/g
- Infus6 (Visit 7): Rate of transmural ileal [ Time Frame: 2 years ]ileum subscore stage 0 (score = 0)
- Infus6 (Visit 7): Rate of colonic healing [ Time Frame: 2 years ]all segments of colon subscore stage 0 (score = 0)
- Infus6 (Visit 7): Rate of total bowel healing [ Time Frame: 2 years ]total ileum and colonic subscore is not greater than stage 0 on either individual score
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||6 Years to 22 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Written informed consent form from the patient (≥18 years old) or from parent/legal guardian if patient is <18 years old.
- Written informed assent form from patient ≥11 years old.
- Age criteria: ≥6 years to ≤22 years of age.
- Diagnosis of Crohn's Disease
- Starting infliximab (or biosimilar)
- Anti-TNF naïve (never received infliximab, adalimumab, golimumab, certolizumab or anti-TNF biosimilar)
- Fecal calprotectin >250 µg/g or fecal lactoferrin >10 µg/g (up to 6 weeks prior to starting infliximab) or endoscopic evidence of active Crohn's disease (up to 90 days prior to starting infliximab)
- wPCDAI >12.5 (up to 6 weeks) prior to the first infliximab infusion
- Negative urine pregnancy test for ALL female subjects
- Negative TB (tuberculosis) blood test
- Diagnosis of ulcerative colitis or inflammatory bowel disease-unspecified
- Prior treatment with infliximab, adalimumab, certolizumab or golimumab (or anti-TNF biosimilar)
- Active or prior evidence in past 12 months of internal (abdominal/pelvic) penetrating fistula(e)
- Active intestinal stricture (luminal narrowing with pre-stenotic dilation >3mm), intra-abdominal abscess or perianal abscess
- Active Clostridium difficile infection or other known bacterial/viral gastroenteritis in last two weeks
- Current ileostomy, colostomy, ileoanal pouch, and/or previous extensive small bowel resection leading to short bowel syndrome
- History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)
- Treatment with another investigational drug within four weeks.
- Treatment with intravenous antibiotics within four weeks.
- Planned continuation of 6-mercaptopurine or azathioprine (Imuran) during study.
- Planned continuation of methotrexate during study.
- Treatment with intravenous corticosteroids within two weeks.
- Currently pregnant, breast feeding or plans in next 12 months to become pregnant
- Inability or failure to provide informed assent/consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04974099
|Contact: Phillip Minar, MD, MSemail@example.com|
|United States, Ohio|
|Cincinnati Children's Hospital||Recruiting|
|Cincinnati, Ohio, United States, 45229|
|Contact: Kimberly Jackson firstname.lastname@example.org|
|Principal Investigator: Phillip Minar, MD, MS|
|Principal Investigator:||Phillip Minar, MD, MS||Children's Hospital Medical Center, Cincinnati|
|Responsible Party:||Children's Hospital Medical Center, Cincinnati|
|Other Study ID Numbers:||
|First Posted:||July 23, 2021 Key Record Dates|
|Last Update Posted:||January 26, 2023|
|Last Verified:||January 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Inflammatory Bowel Diseases
Digestive System Diseases